2021
DOI: 10.2147/opth.s301878
|View full text |Cite
|
Sign up to set email alerts
|

Comparison of Safety and Efficacy of Intrastromal Injections of Voriconazole, Amphotericin B and Natamycin in Cases of Recalcitrant Fungal Keratitis: A Randomized Controlled Trial

Abstract: Objective To compare the safety and efficacy of intrastromal voriconazole (IS-VCZ), amphotericin B (IS-AMB) and natamycin (IS-NTM) as an adjunct to topical natamycin (NTM) in cases of recalcitrant fungal keratitis. Design Prospective randomized trial. Setting Tertiary eye centre. Participants Sixty eyes of 60 patients with microbiologically proven recalcitrant fungal keratitis (ulcer size >2 mm, depth >50% of strom… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
30
0
3

Year Published

2021
2021
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 17 publications
(33 citation statements)
references
References 27 publications
0
30
0
3
Order By: Relevance
“…The mean duration of healing was shorter in the group treated with intrastromal NAT. Higher rates of vascularization were reported in the AMB group [ 81 ].…”
Section: Antifungalsmentioning
confidence: 95%
“…The mean duration of healing was shorter in the group treated with intrastromal NAT. Higher rates of vascularization were reported in the AMB group [ 81 ].…”
Section: Antifungalsmentioning
confidence: 95%
“…The intrastromal injection of amphotericin B has been found to be useful in indolent keratitis caused by Candida and other species. A higher rate of deep vascularization on healing was noted with intrastromal amphotericin B in a recent [88] comparison of intrastromal voriconazole, amphotericin B and natamycin. The relatively smaller number of patients and adjunctive use of other topical or systemic antifungal agents preclude a convincing conclusion on intrastromal usage.…”
Section: Amphotericin Bmentioning
confidence: 87%
“…Natamycin solution at a concentration of 1% for topical use and 0.01% for intrastromal injection was evaluated for efficacy and toxicity in rabbit models and was found non-inferior to a 5% commercially available natamycin suspension. A clinical study [88] comparing the intrastromal use of this solution form of natamycin and other commonly used agents like voriconazole and amphotericin B showed this formulation to have significantly better mean healing time than the other two groups. Further studies with larger sample sizes need to be undertaken in this regard for better validation of this novel natamycin solution.…”
Section: Antifungal Agents 41 Natamycinmentioning
confidence: 97%
See 2 more Smart Citations